Cell-Based Assays Market Size to Hit USD 34.8 Billion by 2030

According to Nova one advisor, the global Cell-based Assays market size is expected to hit around USD 34.8 billion by 2030 from valued at USD 15.95 billion in 2021 and growing at a CAGR of 8.75% from 2022 to 2030

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7333

Key Takeaways:

  • The assay kits products segment accounted for the largest revenue share in 2021 due to the utilitarian benefits that a test kit could offer to clinicians, researchers, and the normal population
  • Ready-to-use kits and self-administrable diagnostic kits are increasingly trending these days
  • The drug discovery application segment is expected to grow at a lucrative CAGR over the forecast period
  • This is due to a rise in the number of researches for therapeutic drug discovery, an increasing number of FDA approvals, and a rise in demand for novel therapeutic drugs coupled with increasing cases of genetic disorders, cancers, & infectious diseases
  • The academic & research institutes end-use segment is expected to register the fastest CAGR over the forecast period
  • The growth can be attributed to the greater utility of cell-based assays for the diagnosis of cancers, genetic disorders, and infectious diseases

A rise in demand for cell-based assays will drive the market. Cell-based assays effectively aid in acceleration and thereby, enhancement of drug development. This helps therapeutic drugs to be supplied robustly to cater to the industry demand. For instance, these are used in lead candidate selection and provide invaluable information about therapeutic action mechanisms, drug efficacy, safety, and toxicity tests. Wide applications of these assays in drug development processes are expected to boost the demand. These assays are integral to the drug development process by adopting several technologies, such as CRISPR-Cas9, to allow easy resolution of mutations, knock-ins & knockouts of a specific marker at a precise location on the genome or a given culture of cells.

For instance, Celprogen’s human pancreatic cancer cell line characterization kit is a cell-based ELISA kit that is used for the measurement of the concentration of a protein in cells for the determination of the differentiation status of stem cells, thereby eliminating the need to prepare cell lysates and is widely applicable for drug discovery. On the other hand, key players are undertaking various growth strategies to expand their pipelines, portfolios, and offerings to penetrate the market better. For instance, in July 2022, Mission Bio, Inc., launched assay for the detection of solid tumors through its pharma assay development services to aid the acceleration of the development process of cancer therapeutics by reducing the time & cost to characterize solid tumors.

Moreover, in April 2022, Porvair Sciences exhibited Chromatrap chip kits for epigenetics along with a new range of assay and newly designed cell culture microplates for high throughput screening process, cell growth, and proliferation at the American Association for Cancer Research. Many researchers and clinicians believe that there is a strong necessity for novel cell-based assays for their utility in diagnostics and to devise new therapeutic regimes to effectively combat the growing burden of autoimmune diseases, infectious diseases, and genetic disorders across the globe. Furthermore, the COVID?19 pandemic was substantially disruptive both to the continuance of research activities and the type of assays performed.

There are efforts across the U.S. to ensure re-igniting the research activities inclusive of all kinds of cell-based assays. These assays are used for the detection of COVID-19 infection as well. For instance, in May 2020, AcroBiosystem launched a flow cytometry assay to study the binding between ACE2 and S1 protein/S1 RBD protein, thus can be utilized for neutralizing antibody screening. North America dominated the global industry in 2021 owing to an increasing number of biotechnology research studies, growing research on therapeutic drugs, the presence of key players, and the high prevalence of cancer. Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 due to the rising demand for research in life sciences and increased genetic level understanding of diseases.

Report Scope of the Cell-based Assays Market

Report Coverage


Market Size

USD xx Billion by 2030

Growth Rate

CAGR of xx% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Product & services, application, end-use and Region,

Companies Mentioned

 BD; CorningInc.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific Inc.; Merck KGaA; Danaher Corp.; Charles River Laboratories; Lonza; Promega Corp.; F. Hoffmann-La Roche Ltd. (Roche Holdings AG)

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7333


Products & Services Insights

On the basis of products & services, the global industry has been further categorized into reagents, assay kits, microplates, probes & labels, instruments & software, and cell lines. The assay kits products & services segment dominated the global industry in 2021 and accounted for the maximum share of more than 39.5% of the overall revenue. The segment is projected to expand further at the fastest growth rate retaining its leading position throughout the forecast period. This can be attributed to its utility in various biopharmaceutical applications.

These particular assay kits significantly cut down ambiguity by offering reliable outcomes in diagnostics, and therefore have a high demand. Moreover, its comprehensive approach of offering all the consumables for the assay drives the segment. For instance, instaCELL Skin Sensitization Assay Kit (by Accelerate) detects early key events of the skin sensitization process, thereby the KeratinoSens (keratinocyte cell lines) express the luciferase reporter gene upon activation.

Application Insights

On the basis of applications, the global industry has been further categorized into basic research, drug discovery, and other applications. The drug discovery application segment dominated the global industry in 2021 and accounted for the maximum share of more than 40.10% of the overall revenue. This growth is attributed to the growing demand for novel therapeutic drugs for the treatment of various diseases across the globe. The growth of the drug discovery segment is boosted by a rise in the number of research for therapeutic drug discovery and growing competition for FDA approvals among the market players.

For instance, in August 2022, FDA approved cell-based gene therapy to treat subjects with Beta-thalassemia requiring a regular blood transfusion process. Furthermore, basic research application is expected to garner a significant industry share over the forecast period. To better understand numerous cellular events in health and illness, cell-based assays act as the core of life sciences research. These assays are used to identify an impact or event within a cell, study gene, protein, or whole-cell activities and the regulatory mechanisms controlling them, and screen for possible inducers or inhibitors of biological processes.

End-use Insights

The pharmaceutical & biotechnology companies end-use segment dominated the global industry in 2021 and accounted for the highest share of more than 51.80% of the overall revenue. In the pharmaceutical industry, cell-based assays are effective for assessing the impact of external stimuli or pharmacological molecules on general cellular function. Furthermore, to choose promising lead molecule candidates from thousands of chemical compound libraries, cell-based drug screening assays have been widely employed in drug discovery research. Such broad applications of cell-based assays in the pharmaceutical industry drive segment growth.

The academic & research institutes end-use segment is expected to witness the fastest CAGR during the forecast period. The growth can be attributed to the rising adoption of these assays for cell-based research and the devising of novel assay-based diagnostics. For instance, in May 2022, the Genetics Institute of America and OneCellDx entered into a strategic agreement for the commercialization of its OneCellDx OncoPredikt kit, which enables the detection of Homologous Recombination Deficiency in cancer patients. Moreover, cell-based assays encourage research in the field of cancer, immunology, stem cells, immunology, and others.

Regional Insights

On the basis of geographies, the global industry has been further categorized into North America, Middle East & Africa, Latin America, Europe, and the Asia Pacific. The North American region dominated the global industry in 2021 and accounted for the maximum share of more than 42.5% of the overall revenue. The region is anticipated to expand further at a steady growth rate maintaining its leading position throughout the forecast period. Market growth in the North American region is mainly attributed to the extensive research carried out in various research institutes collaboratively sponsored by academic research institutes and pharmaceutical giants across the region.

For instance, in April 2022, Labcorp signed a collaboration with Xcell Biosciences, Inc., for the advancement of critical laboratory work focused on improving the safety and efficacy of Cell & Gene Therapies (CGTs) to help effective introduction of innovative CGTs to the market. The rising demand for novel therapeutic drugs in the Asia Pacific is expected to play a major role in the regional market growth. Furthermore, rapid infrastructural development and increasing R&D investment by governments are other factors that are boosting regional growth. Many research studies are sponsored by pharmaceutical giants in the region, resulting in increased demand for cell-based assays for various applications.

Some of the prominent players in the Cell-based Assays Market include:

  • BD
  • Bio-Rad Laboratories, Inc.
  • Corning Inc.
  • Charles River Laboratories
  • Danaher Corp.
  • F. Hoffmann-La Roche Ltd. (Roche Holdings AG)
  • Lonza
  • Merck KGaA
  • Promega Corp.
  • Thermo Fisher Scientific Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cell-based Assays market

  • Products & Services
    • Reagents
    • Assay Kits
      • Cell Growth Assays
      • Reporter Gene Assays
      • Cell Death Assays
      • Second Messenger Assays
    • Microplates
    • Probes & Labels
    • Instruments & Software
    • Cell Lines
      • Primary Cell Lines
      • Stem Cell Lines
      • Immortalized Cell Lines
  • Application
    • Basic Research
    • Drug Discovery
    • Other Applications
  • End-use
    • Pharmaceutical and Biotechnology Companies
    • Academic & Research Institutes
    • Contract Research Organizations

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7333

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/



Back to news